{"product_id":"sens-vrio-analysis","title":"Senseonics Holdings, Inc. (SENS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eCan Senseonics Holdings, Inc. (SENS) truly sustain its market advantage? This essential VRIO analysis distills whether its key assets possess the necessary Value, Rarity, Inimitability, and Organization to secure long-term success. Dive in now to reveal the definitive verdict on its competitive durability.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenseonics Holdings, Inc. (SENS) - VRIO Analysis: Proprietary 365-Day Implantable Sensor Technology (Eversense 365)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core differentiator for Senseonics Holdings, Inc. (SENS): the Eversense 365 sensor. This isn't just another incremental update; it’s a fundamental shift in patient burden for continuous glucose monitoring (CGM).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Reducing Patient Burden\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value proposition here is clear: a full year of monitoring versus the 10-14 day patch changes common with competitors like Dexcom and Abbott. This drastically cuts down on user hassle. The market is responding, too; in Q3 2025, Senseonics reported revenue of \u003cstrong\u003e$8.1 million\u003c\/strong\u003e, a \u003cstrong\u003e90%\u003c\/strong\u003e jump year-over-year, with U.S. new patient starts up \u003cstrong\u003e160%\u003c\/strong\u003e, showing patients value this convenience.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: The Only One-Year Option\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHonestly, right now, it’s the world's first and only one-year CGM system. That makes the core technology rare in the current landscape. While competitors offer shorter-wear patches, the \u003cstrong\u003e365-day\u003c\/strong\u003e sensor is unique.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInimitability: IP and Biocompatibility Hurdles\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImitating this is tough. It requires deep expertise in long-term biocompatibility - keeping the sensor accurate and safe under the skin for 12 months. This is locked behind significant R\u0026amp;D investment and intellectual property. The complexity of sustained accuracy over 365 days is a major barrier to entry for rivals. Defintely not a simple copycat product.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Transitioning to Full Control\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOrganizationally, they are in a transition phase, which tempers the immediate advantage. They are moving commercial responsibility back from Ascensia Diabetes Care, with full self-commercialization starting in 2026. They are setting up for the future, expecting CE Mark approval by year-end 2025 for a 2026 European launch. The full-year 2025 revenue guidance is between \u003cstrong\u003e$34-38 million\u003c\/strong\u003e, showing they are ramping up operations.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage Assessment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is currently \u003cstrong\u003eTemporary\u003c\/strong\u003e. The technology is superior today, but the market knows longer-wear devices are the next frontier. Competitors are definitely working on their own multi-year implants. The key for Senseonics is leveraging this lead before others catch up, especially as they aim for gross margins between \u003cstrong\u003e35% and 40%\u003c\/strong\u003e for the full 2025 fiscal year.\u003c\/p\u003e\n\n\u003cp\u003eHere is the quick math on where the Eversense 365 stands:\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eKey Supporting Data (2025 Fiscal)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e365-day\u003c\/strong\u003e wear time; \u003cstrong\u003e160%\u003c\/strong\u003e U.S. new patient growth (Q3)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eWorld's first and only one-year CGM system\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eInimitability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eProtected by R\u0026amp;D and long-term biocompatibility IP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eTransitioning commercial control; Full self-commercialization by 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eSuperior now, but rivals are developing longer-wear tech\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: draft the 13-week cash flow view incorporating the expected Q4 reorder dynamics by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenseonics Holdings, Inc. (SENS) - VRIO Analysis: Extensive and Growing Intellectual Property Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates a legal moat around the implantable technology, protecting current products and future pipeline assets like Gemini and Freedom. The pipeline includes the Gemini System with an IDE filing planned by year end \u003cstrong\u003e2025\u003c\/strong\u003e and the Freedom System.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eHigh. The depth of the portfolio is rare for a company of this size, as evidenced by the stated patent counts from the May \u003cstrong\u003e2025\u003c\/strong\u003e Investor Presentation.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eSustained. Patent thickets are very hard and expensive for rivals to navigate or design around, securing the long-term competitive position.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh. The IP is actively managed and cited as a core competitive moat in strategy presentations.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\u003cp\u003eThe intellectual property portfolio underpins the company's market position, which is targeting a U.S. Total Addressable Market (TAM) of more than \u003cstrong\u003e$20 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eCount\/Value\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssued U.S. Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e111\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of May \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssued OUS Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e194\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of May \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePending Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e177\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of May \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 \u003cstrong\u003e2025\u003c\/strong\u003e Preliminary Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. New Patient Growth YoY\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e160%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull-Year \u003cstrong\u003e2025\u003c\/strong\u003e Revenue Outlook\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~$35 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year \u003cstrong\u003e2025\u003c\/strong\u003e Guidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's focus on long-term implantable technology, such as the one-year Eversense® 365 CGM System, is protected by this robust IP foundation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe portfolio protects current products and future pipeline assets, including:\n\u003cul\u003e\n\u003cli\u003eEversense® 365 CGM System\u003c\/li\u003e\n\u003cli\u003eGemini System (IDE filing planned by year end \u003cstrong\u003e2025\u003c\/strong\u003e)\u003c\/li\u003e\n\u003cli\u003eFreedom System (designed with no transmitter)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company executed a \u003cstrong\u003e1-for-20\u003c\/strong\u003e reverse stock split effective October 17, \u003cstrong\u003e2025\u003c\/strong\u003e, reducing shares from approximately \u003cstrong\u003e816 million\u003c\/strong\u003e to approximately \u003cstrong\u003e41 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected \u003cstrong\u003e2025\u003c\/strong\u003e gross margins are guided to be \u003cstrong\u003e35%–40%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenseonics Holdings, Inc. (SENS) - VRIO Analysis: Strategic Control over Commercialization Channel (Post-2025 Transition)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003cstrong\u003eValue\u003c\/strong\u003e: Eliminates revenue-sharing with Ascensia.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 Projection\u003c\/th\u003e\n\u003cth\u003e2026 Projection\u003c\/th\u003e\n\u003cth\u003eAt Scale Projection\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e32.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e70%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe transition is planned for \u003cstrong\u003eJanuary 1, 2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity\u003c\/strong\u003e: Temporary. Reclaiming control is a strategic move, but the capability itself (a direct sales force) is common in medtech.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability\u003c\/strong\u003e: Low. Competitors with existing scale could replicate this, but it requires significant upfront investment.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization\u003c\/strong\u003e: High. The transition is planned for \u003cstrong\u003eJanuary 1, 2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nKey leadership hired: Brian Hansen appointed as Chief Commercial Officer.\n\u003c\/li\u003e\n\u003cli\u003e\nInvestments funded by expanded \u003cstrong\u003e$100 million\u003c\/strong\u003e non-dilutive debt facility with Hercules Capital, Inc. (HTGC).\n\u003c\/li\u003e\n\u003cli\u003e\nFull Year 2025 Global Net Revenue Outlook: approximately \u003cstrong\u003e$34-38 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nFull Year 2025 Gross Margins Expected: between \u003cstrong\u003e32.5%\u003c\/strong\u003e and \u003cstrong\u003e37.5%\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nCash used in operations expected for 2025: approximately \u003cstrong\u003e$60 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenseonics Holdings, Inc. (SENS) - VRIO Analysis: Demonstrated Direct-to-Consumer (DTC) Marketing Effectiveness\n\u003c\/h2\u003e\n\u003cp\u003e\nThe analysis focuses on the effectiveness of Senseonics' Direct-to-Consumer (DTC) marketing strategy as a source of competitive advantage.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eDemonstrated Direct-to-Consumer (DTC) Marketing Effectiveness\u003c\/strong\u003e\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Drives patient demand directly, evidenced by a 160% increase in U.S. new patient starts in Q3 2025 over the prior year.\n\u003c\/p\u003e\n\u003cp\u003e\nThe Q3 2025 results highlight this value driver:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year growth of \u003cstrong\u003e90%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. New Patient Starts Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e160%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year in Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC Patient Leads Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e300%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year in Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC Patient Leads Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSequentially in Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Patients from DTC\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e60%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIn Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHighest Monthly New Patient Starts\u003c\/td\u003e\n\u003ctd\u003eOccurred in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCompany History\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Users Switching from Competitors\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e90%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eOf new users in Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. DTC is standard in the CGM space, but their specific success rate is unique to their product messaging.\n\u003c\/p\u003e\n\u003cp\u003e\nThe high conversion rate of leads into new patients suggests a relative rarity in message resonance, despite the commonality of the channel.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can copy ad spend, but the resonance with the implantable value proposition is harder to match.\n\u003c\/p\u003e\n\u003cp\u003e\nWhile competitors can increase advertising spend, the unique nature of the implantable, one-year sensor drives specific patient interest.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nQ3 2025 Selling, General and Administrative (SG\u0026amp;A) expenses rose to \u003cstrong\u003e$15.3 million\u003c\/strong\u003e, primarily due to higher personnel, promotional, and sales commission expenses related to DTC investments.\n\u003c\/li\u003e\n\u003cli\u003e\nEon Care, the insertion network, now supports approximately \u003cstrong\u003e1\/4\u003c\/strong\u003e of all insertions nationwide.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. They are actively investing in this channel, which is clearly paying off in patient acquisition.\n\u003c\/p\u003e\n\u003cp\u003e\nThe company's financial structure and focus support the execution of this strategy.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Restricted Cash, and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$111.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt and Accrued Interest\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$35.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Gross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2025 Revenue Guidance (Narrowed)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$35 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2025 Gross Margin Expectation\u003c\/td\u003e\n\u003ctd\u003eBetween \u003cstrong\u003e35% and 40%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary.\n\u003c\/p\u003e\n\u003cp\u003e\nThe advantage is temporary as competitors are expected to increase their own DTC spending to counter the lead generation success.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenseonics Holdings, Inc. (SENS) - VRIO Analysis: Next-Generation Product Pipeline (Gemini and Freedom)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a clear path beyond the current transmitter-based system, with Gemini aiming for a self-powering implant and Freedom eliminating the external transmitter entirely. Eversense 365 is the foundational base for these next-generation systems.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Having two distinct, advanced follow-on systems in development is a strong sign of R\u0026amp;D capability, with milestones including the progression of the Gemini system.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Developing next-gen hardware is capital-intensive and requires specialized engineering talent, evidenced by Research and Development Expenses of $10.5 million in Q3 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. They are advancing these, with an FDA IDE submission for Gemini planned by year-end 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary.\u003c\/p\u003e\n\u003cp\u003eThe pipeline progression is supported by recent financial allocations and defined regulatory targets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA IDE submission for Gemini is planned by the end of 2025.\u003c\/li\u003e\n\u003cli\u003eThe company expects its cash runway to extend through the development and commercialization of next-generation platforms into fiscal 2027.\u003c\/li\u003e\n\u003cli\u003eResearch and Development Expenses were $10.5 million in Q3 2024, decreasing to $7.8 million in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eAnticipated full-year 2025 global net revenue guidance is approximately $35 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe specific timelines for the next-generation platforms are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eGemini System\u003c\/td\u003e\n\u003ctd\u003eFreedom System\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Status\/Next Step\u003c\/td\u003e\n\u003ctd\u003eSystem on track to begin FDA Investigational Device Exemption (IDE) study\u003c\/td\u003e\n\u003ctd\u003eRemains in prototype testing; Functional system earmarked for Q4 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Date for IDE Study Start\u003c\/td\u003e\n\u003ctd\u003eLater in 2025 or by year-end 2025\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated, follows Gemini development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Pivotal Study\u003c\/td\u003e\n\u003ctd\u003eQ4 2026\u003c\/td\u003e\n\u003ctd\u003eQ4 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Commercial Launch\u003c\/td\u003e\n\u003ctd\u003eQ4 2026\u003c\/td\u003e\n\u003ctd\u003eQ4 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial context surrounding the pipeline development includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, restricted cash and short-term investments as of September 30, 2024, totaled $74.8 million.\u003c\/li\u003e\n\u003cli\u003eCash balance as of September 30, 2025, was $111.3 million.\u003c\/li\u003e\n\u003cli\u003eExpected cash utilization for full-year 2025 is approximately $60 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenseonics Holdings, Inc. (SENS) - VRIO Analysis: High Accuracy Profile (Low MARD)\n\u003c\/h2\u003e\n\u003cp\u003eThe core value proposition of the Eversense system is its long-term, implantable nature coupled with high accuracy.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe Eversense 365 sensor demonstrated an overall Mean Absolute Relative Difference (MARD) of \u003cstrong\u003e8.8%\u003c\/strong\u003e against the Yellow Springs Instrument (YSI) in the ENHANCE clinical study, achieved with primarily \u003cstrong\u003eone calibration per week\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe confirmed alert detection rate at \u003cstrong\u003e180 mg\/dL\u003c\/strong\u003e was \u003cstrong\u003e97.9%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eEversense 365 (ENHANCE Study)\u003c\/td\u003e\n\u003ctd\u003eEversense E3 (PROMISE Study)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall MARD\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor Survival (Max Wear)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e90%\u003c\/strong\u003e at day \u003cstrong\u003e365\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e65%\u003c\/strong\u003e at day \u003cstrong\u003e180\u003c\/strong\u003e (Primary Sensors)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlert Detection Rate (\u0026lt;70 mg\/dL)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e96.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e94%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlert Detection Rate (\u0026gt;180 mg\/dL)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e97.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e99%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eAchieving a MARD of \u003cstrong\u003e8.8%\u003c\/strong\u003e over a \u003cstrong\u003e365-day\u003c\/strong\u003e period is a technical feat, though other contemporary CGMs achieve low MARDs over shorter durations.\u003c\/p\u003e\n\u003cp\u003eSensor longevity data from a feasibility study indicated a sensor longevity of \u003cstrong\u003e97%\u003c\/strong\u003e through \u003cstrong\u003e365 days\u003c\/strong\u003e for a modified system.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe sustained accuracy is intrinsically linked to the core sensor chemistry and the proprietary design of the long-term implantable technology, which is protected by intellectual property.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSensor survival was \u003cstrong\u003e92%\u003c\/strong\u003e at day \u003cstrong\u003e330\u003c\/strong\u003e and \u003cstrong\u003e90%\u003c\/strong\u003e at day \u003cstrong\u003e365\u003c\/strong\u003e in the ENHANCE study.\u003c\/li\u003e\n\u003cli\u003eThe system requires only \u003cstrong\u003etwo\u003c\/strong\u003e sensor insertion and removal procedures per year for 365-day wear.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThis metric is leveraged in commercial strategy, as evidenced by Senseonics expecting full-year 2025 global net revenue to be approximately \u003cstrong\u003e$35 million\u003c\/strong\u003e, driven by the rollout of Eversense 365.\u003c\/p\u003e\n\u003cp\u003eU.S. revenue for Q3 2025 was \u003cstrong\u003e$6.4 million\u003c\/strong\u003e, up from \u003cstrong\u003e$2.4 million\u003c\/strong\u003e in Q3 2024.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe combination of long-term wear and low MARD provides a \u003cstrong\u003eTemporary\u003c\/strong\u003e advantage, contingent on continued R\u0026amp;D outpacing competitors' development of comparable long-duration accuracy.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenseonics Holdings, Inc. (SENS) - VRIO Analysis: Established, Though Small, Global Installed Patient Base\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eProvides a recurring revenue base and a foundation for future growth.\u003c\/p\u003e\n\u003cp\u003eThe global installed patient base was approximately \u003cstrong\u003e6,000\u003c\/strong\u003e as of the end of 2024.\u003c\/p\u003e\n\u003cp\u003eThe full-year 2025 financial outlook assumes approximately doubling the global patient base, targeting 12,000 users.\u003c\/p\u003e\n\u003cp\u003eFull Year 2024 Total Revenue was approximately \u003cstrong\u003e$22.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eFull-year 2025 global net revenue is projected to be approximately \u003cstrong\u003e$34-38 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (End of 2024\/FY2024)\u003c\/td\u003e\n\u003ctd\u003eProjection (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Installed Patient Base\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e6,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e12,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$34-38 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/h\u003e\u003ch\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eLow; Senseonics is a small player in the CGM market.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePatient base increased \u003cstrong\u003e56%\u003c\/strong\u003e in 2024 over 2023.\u003c\/li\u003e\n\u003cli\u003eNew patient shipments in December 2024 reached approximately \u003cstrong\u003e600\u003c\/strong\u003e, the highest monthly total in company history.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/h\u003e\u003ch\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eLow; it is a historical artifact of past sales and partnerships.\u003c\/p\u003e\n\u003c\/h\u003e\u003ch\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eModerate; focused on retention and growth from this base.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company executed a restructuring process with a target cash operating expense reduction of \u003cstrong\u003e$10 million\u003c\/strong\u003e in 2025.\u003c\/li\u003e\n\u003cli\u003eThe number of patients switching to Eversense from competitive CGMs increased \u003cstrong\u003e49%\u003c\/strong\u003e since the Eversense 365 launch.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e118%\u003c\/strong\u003e increase in patient referrals from physicians since the Eversense 365 launch.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/h\u003e\u003ch\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eNone.\u003c\/p\u003e\n\u003c\/h\u003e\u003ch\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenseonics Holdings, Inc. (SENS) - VRIO Analysis: Recent Balance Sheet Strengthening (Capital Raise)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The $77.8 million in aggregate gross proceeds from the May 2025 capital raise, comprising $57.5 million from the public offering and approximately $20.3 million from the private placement with Abbott Laboratories, strengthens the balance sheet, resulting in over $126 million in cash as of June 30, 2025, to fund the commercial transition.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eComponent\u003c\/th\u003e\n\u003cth\u003eGross Proceeds (USD)\u003c\/th\u003e\n\u003cth\u003eShares Sold (Approx.)\u003c\/th\u003e\n\u003cth\u003eClosing Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Offering (Net of Underwriter Option)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$57.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e115,000,000 shares\u003c\/td\u003e\n\u003ctd\u003eMay 21, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbbott Private Placement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e40,539,265 shares\u003c\/td\u003e\n\u003ctd\u003eMay 21, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTotal Gross Proceeds\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$77.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eMay 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Access to capital markets is not unique, but securing non-dilutive debt and equity is timely. The concurrent private placement with Abbott Laboratories, resulting in 4.99% ownership post-closing, provides a strategic anchor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Capital access depends on market sentiment and creditworthiness. The ability to secure a strategic investment from a major industry player like Abbott at the public offering price of $0.50 per share demonstrates specific market timing and relationship leverage.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The funds are explicitly earmarked to support launch and development initiatives. The intended use of net proceeds includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFunding the ongoing launch of Eversense 365.\u003c\/li\u003e\n\u003cli\u003eContinued development of pipeline products, such as the Gemini and Freedom systems.\u003c\/li\u003e\n\u003cli\u003eWorking capital and general corporate purposes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The capital infusion provides a runway to execute the Eversense 365 commercial strategy and advance R\u0026amp;D, but the advantage is temporary until sustained commercial success or further innovation is achieved.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSenseonics Holdings, Inc. (SENS) - VRIO Analysis: Key Leadership Transition for Self-Commercialization (Hansen)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eKey Leadership Transition for Self-Commercialization (Hansen)\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eBringing in Brian Hansen, former President of CGM at Ascensia, as CCO on \u003cstrong\u003eJanuary 1, 2026\u003c\/strong\u003e, ensures continuity and deep commercial expertise for the new self-run model. Hansen previously oversaw CGM commercialization at Ascensia.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Hiring top talent from a partner is a strategic advantage, but not unheard of.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eModerate. Competitors can try to poach talent, but securing this specific leader for this specific transition is unique.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh. This move is a clear signal of organizational readiness for the \u003cstrong\u003e2026\u003c\/strong\u003e shift, which includes assuming responsibility for all U.S. sales, marketing and commercialization beginning \u003cstrong\u003eJanuary 1, 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial Projections Comparison Post-Transition:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003e2025 Projection\/Actual Data\u003c\/td\u003e\n\u003ctd\u003e2026 Projection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e32.5%\u003c\/strong\u003e to \u003cstrong\u003e37.5%\u003c\/strong\u003e (Projected) or \u003cstrong\u003e35%\u003c\/strong\u003e to \u003cstrong\u003e40%\u003c\/strong\u003e (Updated Q3 2025 Expectation)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-Term Gross Margin Potential\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eExceeding \u003cstrong\u003e70%\u003c\/strong\u003e at scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Net Revenue\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$34–$38 million\u003c\/strong\u003e (Outlook) or \u003cstrong\u003e~$35 million\u003c\/strong\u003e (Investor Presentation)\u003c\/td\u003e\n\u003ctd\u003eTopline accretion of at least \u003cstrong\u003e20%\u003c\/strong\u003e (Goal)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Facility for Commercial Organization\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$100 million\u003c\/strong\u003e expanded non-dilutive debt facility\u003c\/td\u003e\n\u003ctd\u003eCash position to fund near-term commercial investments (Goal)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eLatest Statistical and Financial Data Points:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Net Revenue: \u003cstrong\u003e$8.1 million\u003c\/strong\u003e, a \u003cstrong\u003e90%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Profit: \u003cstrong\u003e$3.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 New Patient Shipments: \u003cstrong\u003e160%\u003c\/strong\u003e growth over the prior-year period.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Patient Leads from DTC: \u003cstrong\u003e300%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eEon Care represents approximately \u003cstrong\u003e1\/4\u003c\/strong\u003e of all insertions nationwide.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFinalize the \u003cstrong\u003e2026\u003c\/strong\u003e gross margin projection model incorporating the self-commercialization costs by next Wednesday. The model must align with the projected \u003cstrong\u003e15%–20%\u003c\/strong\u003e gross profit margin expansion goal for \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516248318101,"sku":"sens-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sens-vrio-analysis.png?v=1740214195","url":"https:\/\/dcf-model.com\/fr\/products\/sens-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}